Physicians

Department / Division
Medicine / Med-Rheumatolgy & Immunology

Address
DUMC 3440
Durham, NC 27710

Appointment Telephone
919-613-2243

Office Telephone
919-684-2965

Fax Telephone
919-684-8358

Training

• MD, Tufts University School of Medicine (Massachusetts), 1978

Residency

• Medicine, Duke University Medical Center, 1978-1981
• Rheumatology, Duke University Medical Center, 1981-1983

Clinical Interests
Systemic vasculitis, Wegener's granulomatosis, temporal arteritis, Takayasu arteritis, systemic lupus erythematosus, erosive osteoarthritis, antiphospholipid antibody syndrome, women with rheumatic disease, Behcet's syndrome, retroperitoneal fibrosis

Research Interests
My clinical research interests include systemic vasculitis (Wegener's granulomatosis, microscopic polyangiitis, giant cell arteritis, Takayasu arteritis) and multi-disciplinary efforts in the areas of systemic lupus erythematosus and anti-phospholipid syndrome.  Dr. E. William St. Clair and I represented Duke in the Wegener's granulomatosis etanercept trial (WGET), a multi-center effort to assess the addition of etanercept to traditional therapy in limited and severe forms of this type of vasculitis, and the RAVE trial, a multi-center, double-blind, controlled trial comparing rituximab with cyclophosphamide in patients with ANCA-associated vasculitis.  

My area of clinical expertise is also in the study of vasculitides, particularly Wegener's granulomatosis, giant cell arteritis, and Takayasu's arteritis, as well as systemic lupus erythematosus, anti-phospholipid syndrome, and women's health related to rheumatic disease conditions. Key words:  vasculitis, systemic vasculitis, Wegener's granulomatosis, giant cell (temporal) arteritis, Takayasu arteritis, anti-phospholipid antibody syndrome.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Genentech, Inc (Roche Holding)

Representative Publications
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. (2010) Abstract

The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis.  NEJM 2005; 352(4): 19-29. (2005)

Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune J, Ytterberg SR, Allen NB, Stone JH, . Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005 Dec;118(12):1416. (2005) Abstract

WGET Research Group, Stone JH, Allen NB, et al.  Limited vs. Severe Wegener's granulomatosis.  Arthritis Rheum 2003; 48:2299-2309. (2003)

Hansen KE, Moore KD, Ortel TL, Allen NB. Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis Rheum. 1999 Oct;42(10):2250-2. (1999) Abstract